Cargando…
A radiobiological model of metastatic burden reduction for molecular radiotherapy: application to patients with bone metastases
Skeletal tumour burden is a biomarker of prognosis and survival in cancer patients. This study proposes a novel method based on the linear quadratic model to predict the reduction in metastatic tumour burden as a function of the absorbed doses delivered from molecular radiotherapy treatments. The ra...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
IOP Publishing
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5953197/ https://www.ncbi.nlm.nih.gov/pubmed/28291739 http://dx.doi.org/10.1088/1361-6560/aa5e6f |
_version_ | 1783323327905923072 |
---|---|
author | Denis-Bacelar, Ana M Chittenden, Sarah J Murray, Iain Divoli, Antigoni Ralph McCready, V Dearnaley, David P O’Sullivan, Joe M Johnson, Bernadette Flux, Glenn D |
author_facet | Denis-Bacelar, Ana M Chittenden, Sarah J Murray, Iain Divoli, Antigoni Ralph McCready, V Dearnaley, David P O’Sullivan, Joe M Johnson, Bernadette Flux, Glenn D |
author_sort | Denis-Bacelar, Ana M |
collection | PubMed |
description | Skeletal tumour burden is a biomarker of prognosis and survival in cancer patients. This study proposes a novel method based on the linear quadratic model to predict the reduction in metastatic tumour burden as a function of the absorbed doses delivered from molecular radiotherapy treatments. The range of absorbed doses necessary to eradicate all the bone lesions and to reduce the metastatic burden was investigated in a cohort of 22 patients with bone metastases from castration-resistant prostate cancer. A metastatic burden reduction curve was generated for each patient, which predicts the reduction in metastatic burden as a function of the patient mean absorbed dose, defined as the mean of all the lesion absorbed doses in any given patient. In the patient cohort studied, the median of the patient mean absorbed dose predicted to reduce the metastatic burden by 50% was 89 Gy (interquartile range: 83–105 Gy), whilst a median of 183 Gy (interquartile range: 107–247 Gy) was found necessary to eradicate all metastases in a given patient. The absorbed dose required to eradicate all the lesions was strongly correlated with the variability of the absorbed doses delivered to multiple lesions in a given patient (r = 0.98, P < 0.0001). The metastatic burden reduction curves showed a potential large reduction in metastatic burden for a small increase in absorbed dose in 91% of patients. The results indicate the range of absorbed doses required to potentially obtain a significant survival benefit. The metastatic burden reduction method provides a simple tool that could be used in routine clinical practice for patient selection and to indicate the required administered activity to achieve a predicted patient mean absorbed dose and reduction in metastatic tumour burden. |
format | Online Article Text |
id | pubmed-5953197 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | IOP Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-59531972018-05-18 A radiobiological model of metastatic burden reduction for molecular radiotherapy: application to patients with bone metastases Denis-Bacelar, Ana M Chittenden, Sarah J Murray, Iain Divoli, Antigoni Ralph McCready, V Dearnaley, David P O’Sullivan, Joe M Johnson, Bernadette Flux, Glenn D Phys Med Biol Paper Skeletal tumour burden is a biomarker of prognosis and survival in cancer patients. This study proposes a novel method based on the linear quadratic model to predict the reduction in metastatic tumour burden as a function of the absorbed doses delivered from molecular radiotherapy treatments. The range of absorbed doses necessary to eradicate all the bone lesions and to reduce the metastatic burden was investigated in a cohort of 22 patients with bone metastases from castration-resistant prostate cancer. A metastatic burden reduction curve was generated for each patient, which predicts the reduction in metastatic burden as a function of the patient mean absorbed dose, defined as the mean of all the lesion absorbed doses in any given patient. In the patient cohort studied, the median of the patient mean absorbed dose predicted to reduce the metastatic burden by 50% was 89 Gy (interquartile range: 83–105 Gy), whilst a median of 183 Gy (interquartile range: 107–247 Gy) was found necessary to eradicate all metastases in a given patient. The absorbed dose required to eradicate all the lesions was strongly correlated with the variability of the absorbed doses delivered to multiple lesions in a given patient (r = 0.98, P < 0.0001). The metastatic burden reduction curves showed a potential large reduction in metastatic burden for a small increase in absorbed dose in 91% of patients. The results indicate the range of absorbed doses required to potentially obtain a significant survival benefit. The metastatic burden reduction method provides a simple tool that could be used in routine clinical practice for patient selection and to indicate the required administered activity to achieve a predicted patient mean absorbed dose and reduction in metastatic tumour burden. IOP Publishing 2017-04-07 2017-03-14 /pmc/articles/PMC5953197/ /pubmed/28291739 http://dx.doi.org/10.1088/1361-6560/aa5e6f Text en © 2017 Institute of Physics and Engineering in Medicine http://creativecommons.org/licenses/by/3.0/ Original content from this work may be used under the terms of the Creative Commons Attribution 3.0 licence (http://creativecommons.org/licenses/by/3.0) . Any further distribution of this work must maintain attribution to the author(s) and the title of the work, journal citation and DOI. |
spellingShingle | Paper Denis-Bacelar, Ana M Chittenden, Sarah J Murray, Iain Divoli, Antigoni Ralph McCready, V Dearnaley, David P O’Sullivan, Joe M Johnson, Bernadette Flux, Glenn D A radiobiological model of metastatic burden reduction for molecular radiotherapy: application to patients with bone metastases |
title | A radiobiological model of metastatic burden reduction for molecular radiotherapy: application to patients with bone metastases |
title_full | A radiobiological model of metastatic burden reduction for molecular radiotherapy: application to patients with bone metastases |
title_fullStr | A radiobiological model of metastatic burden reduction for molecular radiotherapy: application to patients with bone metastases |
title_full_unstemmed | A radiobiological model of metastatic burden reduction for molecular radiotherapy: application to patients with bone metastases |
title_short | A radiobiological model of metastatic burden reduction for molecular radiotherapy: application to patients with bone metastases |
title_sort | radiobiological model of metastatic burden reduction for molecular radiotherapy: application to patients with bone metastases |
topic | Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5953197/ https://www.ncbi.nlm.nih.gov/pubmed/28291739 http://dx.doi.org/10.1088/1361-6560/aa5e6f |
work_keys_str_mv | AT denisbacelaranam aradiobiologicalmodelofmetastaticburdenreductionformolecularradiotherapyapplicationtopatientswithbonemetastases AT chittendensarahj aradiobiologicalmodelofmetastaticburdenreductionformolecularradiotherapyapplicationtopatientswithbonemetastases AT murrayiain aradiobiologicalmodelofmetastaticburdenreductionformolecularradiotherapyapplicationtopatientswithbonemetastases AT divoliantigoni aradiobiologicalmodelofmetastaticburdenreductionformolecularradiotherapyapplicationtopatientswithbonemetastases AT ralphmccreadyv aradiobiologicalmodelofmetastaticburdenreductionformolecularradiotherapyapplicationtopatientswithbonemetastases AT dearnaleydavidp aradiobiologicalmodelofmetastaticburdenreductionformolecularradiotherapyapplicationtopatientswithbonemetastases AT osullivanjoem aradiobiologicalmodelofmetastaticburdenreductionformolecularradiotherapyapplicationtopatientswithbonemetastases AT johnsonbernadette aradiobiologicalmodelofmetastaticburdenreductionformolecularradiotherapyapplicationtopatientswithbonemetastases AT fluxglennd aradiobiologicalmodelofmetastaticburdenreductionformolecularradiotherapyapplicationtopatientswithbonemetastases AT denisbacelaranam radiobiologicalmodelofmetastaticburdenreductionformolecularradiotherapyapplicationtopatientswithbonemetastases AT chittendensarahj radiobiologicalmodelofmetastaticburdenreductionformolecularradiotherapyapplicationtopatientswithbonemetastases AT murrayiain radiobiologicalmodelofmetastaticburdenreductionformolecularradiotherapyapplicationtopatientswithbonemetastases AT divoliantigoni radiobiologicalmodelofmetastaticburdenreductionformolecularradiotherapyapplicationtopatientswithbonemetastases AT ralphmccreadyv radiobiologicalmodelofmetastaticburdenreductionformolecularradiotherapyapplicationtopatientswithbonemetastases AT dearnaleydavidp radiobiologicalmodelofmetastaticburdenreductionformolecularradiotherapyapplicationtopatientswithbonemetastases AT osullivanjoem radiobiologicalmodelofmetastaticburdenreductionformolecularradiotherapyapplicationtopatientswithbonemetastases AT johnsonbernadette radiobiologicalmodelofmetastaticburdenreductionformolecularradiotherapyapplicationtopatientswithbonemetastases AT fluxglennd radiobiologicalmodelofmetastaticburdenreductionformolecularradiotherapyapplicationtopatientswithbonemetastases |